TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Lumbar spine BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urine N-telopeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number needed to treat
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: false negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of loads within the temporomandibular joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive answers on SEP2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive answers on SEP3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REC gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PH gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of clofazimine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: composite of death/MI/stroke/urgent revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Advancement of the mandible
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in effective mandibular length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of growth-related bite deepening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bleeding on probing (BOP) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dix-Hallpike responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrial fibrillation recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiovascular hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Persistent severe visual loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-calcified plaque component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MEAV50 for femoral nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 of ropivacaine 0.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of proximal DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of overall DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Endothelial cell count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide levels after 15 minutes of OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: breast cancer related mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of death and recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Confidence in performing medication reviews
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in prescribing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effective rate after 6 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPQ scores after 6 months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: MPQ scores after 6 months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Residual filling material in dentinal tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exertional dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: successful pregnancy termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Presence of carotid plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall improvement in Oral Health-Related Quality of Life (OHRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Received social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Left atrial volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum inferior vena cava diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tricuspid regurgitation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SUDI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SIIQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Altered sensation classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ED50 for spinal ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 for spinal ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean increase in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for diuretic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bioequivalence of FTC/TDF tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UAER (Urinary Albumin Excretion Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood lymphocyte percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: independence in extended ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adjusted costs
Endpoint domain: Resource use
Primary endpoint: Severity of lumbopelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion rate of DBC vs CC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cecal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of analgesic agent during intubations
Endpoint domain: Adverse events/effects
Primary endpoint: Enzyme activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cognitive deficits 1 week after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: elevated depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug liking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACRP (Adjusted Clinical Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Vessel Revascularisation (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FENO values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchial NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean area under the plasma concentration‐time curve (AUC0‐∞) of buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration (Cmax) of buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t ½) of buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total compensation of the head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total compensation of the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral mucositis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis-related pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of abdominal x-rays for diagnosing intussusception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of abdominal x-rays for diagnosing intussusception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of abnormal renal units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients in strict NEO-RACo remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in Disease Activity Score using 28 joints remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total Sharp/van der Heijde score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieval of emotional information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transfusion requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of throat pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean angina score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with severe angina (class III/IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of angina-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median freedom-from-treatment (FFT) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median freedom from treatment failure (FFTF) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCR of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: beta-cell function (HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: improvement in functioning
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: clinically significant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: TLF (Target Lesion Failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's views towards antidepressants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in anti-inflammatory cytokine IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: all-cause mortality or cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: fecal ROS generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD(4) (+) percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD(4) (+)/CD(8) (+) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of C3 and C4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall mental health improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in dactylitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour reflective total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distant disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: long-term survival benefit of treatment
Endpoint domain: Mortality/survival
Primary endpoint: gD2 and gB2 ELISA antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HSV-2-neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Precursor frequency of gD2- and gB2-specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 10-year curative treatment-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Hospital admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Denture satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: analogue pain scales at 1 week after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trends of analogue pain score progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps in 60 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sICAM‐1 level in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Visual Acuity (VA) of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in VA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bacterial colony forming units (CFUs) in aerosol samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intake of food calories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT interval variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Narrower paced QRS duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shorter QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shorter QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral muscle volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stair-climbing score (Barthel Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: successful BCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: On-task behaviour
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stress reduction (PSS score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety reduction (DASS anxiety score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median number of combined unique active lesions per scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Overall survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of chronic GvHD at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stages of normal puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Late Asthmatic Response (LAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Delta log PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: general psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tear film break-up time test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Likelihood of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: CAVI (Cardio-Ankle Vascular Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of periprocedural ischemic brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: cumulative bowel obstruction percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reliability of HIV antibody testing kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waking salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: excursion ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's choice of the test brand
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systemic analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New dementia diagnoses
Endpoint domain: Mortality/survival
Primary endpoint: Disability (HAQ DI score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hand mobility and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment in serum 25(OH)D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of bone ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of first NMSC
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of BCC
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of SCC
Endpoint domain: Mortality/survival
Primary endpoint: Mood states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of spontaneous movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEAP (Net Endogenous Acid Production)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: posttest smoking initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttest smoking continuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Positive reactions to challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: increase in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: counselling satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: uptake of genetic testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes of sedentary time (ST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood loss during stomach sectioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes